Michelle Bell

A new survey reveals security teams see less than half of AI tools built by employees, creating a massive, unmanaged attack surface inside organizations.

As private equity shifts from financial engineering to operational value, firms are doubling down on supply chain expertise to unlock hidden gains and mitigate risk.

A landmark study reveals essential phospholipids significantly reduce liver fat and fatigue in MASLD patients, offering a new tool against a silent epidemic.

As regulators remove a key barrier to day trading, MoneyFlare's new AI bot aims to give retail investors the speed and precision to compete.

Unilever Food Solutions is ditching static trend reports for a real-time AI platform, promising to level the playing field for restaurants of all sizes.

Swedish fintech Findity brings its AI-powered embedded expense platform to the U.S., partnering with Centime to reshape how businesses manage finances.

Foxit's new app for ChatGPT enables full document workflows inside the chat, tackling AI's 'verification burden' and challenging rivals in the new AI workspace.

A new drug for a life-threatening genetic heart condition begins late-stage trials, earning FDA Fast Track to potentially speed its path to patients.

A major senior living operator rebrands 34 communities, revealing a strategic response to a demographic wave and a looming national housing crisis for older adults.

Sonata Software's new AWS status validates its AI-first approach, positioning it as a key player in the booming cloud modernization market.

A $3.19M Pagani leads a record-breaking $48.5M auction with 100% sell-through, proving the high-end collector car market is thriving.

Derivatives ETF provider VegaShares hires industry veteran Bryan Bondoc, signaling a major push to bring complex structured products to mainstream advisors.

As POSaBIT preps its Q4 earnings call, investors are watching to see if record profits can outweigh falling revenue in the competitive cannabis tech space.

Ionic Digital's Bitcoin output fell in March, but a debt-free strategy and a major AI deal suggest a calculated shift toward long-term stability.

Biogen consolidates worldwide rights for its promising immunology drug felzartamab, acquiring China rights from TJ Biopharma in a strategic $850M deal.

With a new 17,000 sq ft facility, an Idaho tech firm is scaling its revolutionary 3D printing to meet surging aerospace and defense composite demand.

After a decade as Semaphore Solutions, Labbit is going all-in on its LIMS platform. Here’s why the strategic shift matters for regulated laboratories.

A $300M tugboat deal pushes Woodside's investment in Louisiana past $1 billion, boosting the state's maritime industry and its role in global energy.

A new integration for Quantum's CatDV platform ditches AI hype for deterministic data, promising to end manual logging for teams like the Miami HEAT.

Theo is opening its gold-backed, yield-bearing stablecoin globally after it held steady through market chaos, aiming to attract $1 billion by year-end.